Uncategorized

Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis

Published

4 hours ago

on

The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version